Skip to main content
SpringerLink
Log in

The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

We conducted a prognostic analysis of preoperative parameters and Ki-67 determination to develop selection criteria for cytoreductive surgery (CRS) and HIPEC in patients with diffuse malignant peritoneal mesothelioma (DMPM).

Methods

DMPM patients treated with CRS and HIPEC at NCI of Milan participated in this study. Multivariate analysis was conducted using Cox proportional hazard model and conditional inference tree method to select independent predictors of overall survival (OS) from the followings pre-cytoreduction parameters: age, sex, ECOG performance status, Charlson comorbidity index, previous systemic chemotherapy, CA-125, histological subtype (epithelioid vs. biphasic/sarcomatoid), Ki-67 (determined with immunohistochemistry), and peritoneal cancer index (PCI).

Results

A total of 117 patients (male/female: 67/50) with median age of 60.5 (range 22–75) years were included. Eighty-three patients had ECOG performance status = 0, median Charlson comorbidity index was 4 (range 2–9), and 102 cases had epithelioid subtype. Median Ki-67 was 5 % (range 1–60). Ninety-four (80.3 %) cases were optimally cytoreduced. The Cox analysis identified Ki-67, PCI, and histological subtype as independent prognosticators of OS. Conditional inference tree method identified three prognostic subsets: (I) Ki-67 ≤ 9 %; (II) Ki-67 > 9 % and PCI ≤ 17; and (III) Ki-67 > 9 % and PCI > 17. The median OS for subsets I, II, and III were, 86.6, 63.2, and 10.3 months, respectively.

Conclusions

Ki-67 is a powerful prognosticator that allows, along with PCI, and histological subtype, a good prediction of OS in patients with DMPM. Patients with Ki-67 > 9 % and PCI > 17 are unlikely to benefit from the procedure and should be considered for other treatment protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397–40.

    Article  CAS  PubMed  Google Scholar 

  2. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis and pathogenesis. Curr Treat Options Oncol. 2008;9:147–157.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Moore AJ, Parker RJ, Wiggins J. Malignant mesothelioma. Orphanet J Rare Dis. 2008;3:34.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Antman KH, Osteen RT, Klegar KL, et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet. 1985;2:977–81.

    Article  CAS  PubMed  Google Scholar 

  5. Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol. 1999;70:6–12.

    Article  CAS  PubMed  Google Scholar 

  6. Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22:1686–93.

    Article  PubMed  Google Scholar 

  7. Schaub NP, Alimchandani M, Quezado M, et al. A Novel Nomogram for Peritoneal Mesothelioma Predicts Survival. Ann Surg Oncol. 2013;20:555–61.

    Article  PubMed  Google Scholar 

  8. Deraco M, Cabras A, Baratti D, Kusamura S. Immunohistochemical evaluation of minichromosome maintenance protein 7 (MCM7), topoisomerase IIα, and Ki-67 in diffuse malignant peritoneal mesothelioma patients using tissue microarray. Ann Surg Oncol. 2015. doi:10.1245/s10434-015-4498-z.

    Google Scholar 

  9. Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer. 2005;103:839–849.

    Article  PubMed  Google Scholar 

  10. Deraco M, Santoro N, Carraro O, et al. Peritoneal carcinomatosis: feature of dissemination. A review. Tumori. 1999;85:1–5.

    CAS  PubMed  Google Scholar 

  11. Deraco M, Baratti D, Kusamura S, et al. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol. 2009;100:321–8.

    Article  PubMed  Google Scholar 

  12. Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer. 2002; 94:492–499.

    Article  CAS  PubMed  Google Scholar 

  13. Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1093–100.

    Article  PubMed  Google Scholar 

  14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–383.

    Article  CAS  PubMed  Google Scholar 

  15. Mery É, Hommell-Fontaine J, Capovilla M, et al. Peritoneal malignant mesothelioma: review and recent data. Ann Pathol. 2014;34:26–33.

    Article  PubMed  Google Scholar 

  16. Younan R, Kusamura S, Baratti D, et al. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol. 2008;98:253–7.

    Article  PubMed  Google Scholar 

  17. Royston P, Sauerbrei W. Building multivariable regression models with continuous covariates in clinical epidemiology—with an emphasis on fractional polynomials. Methods Inf Med. 2005;44:561–71.

    CAS  PubMed  Google Scholar 

  18. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87.

    Article  PubMed  Google Scholar 

  19. Efron B, Tibshirani RJ. An introduction to the bootstrap. Chapman and Hall, Springer Science, New York, 1993.

    Book  Google Scholar 

  20. Hothorn T ZH. Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat. 2006;15:651–74.

    Article  Google Scholar 

  21. Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49:3140–8.

    Article  PubMed  Google Scholar 

  22. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42.

    Article  PubMed  Google Scholar 

  23. Harrell FE Jr. Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. New York, Springer, 2001.

    Google Scholar 

  24. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006; 25:127–141.

    Article  PubMed  Google Scholar 

  25. Gouy S, Belghiti J, Uzan C, Canlorbe G, Gauthier T, Morice P. Accuracy and reproducibility of the peritoneal cancer index in advanced ovarian cancer during laparoscopy and laparotomy. Int J Gynecol Cancer. 2013;23:1699–703.

    Article  PubMed  Google Scholar 

  26. Nonaka D, Kusamura S, Baratti D, et al. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer. 2005; 104:2181–88.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This study was partially supported by AIRC (Associazione Italiana per la Ricerca Contro il Cancro).

Conflict of interest

The authors declare that there is no conflict of interest.

Financial support

The present work did not receive any financial support.

Author information

Authors and Affiliations

  1. Peritoneal Surface Malignancy Program, Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy

    Shigeki Kusamura MD, PhD, Pilar Adriana Torres Mesa MD, Dario Baratti MD & Marcello Deraco MD

  2. European School of Peritoneal Surface Oncology (ESPSO), Centro Nacional de Oncología S.A, Bogotá, Colombia

    Pilar Adriana Torres Mesa MD

  3. Pathology department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

    Antonello Cabras MD

Authors
  1. Shigeki Kusamura MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pilar Adriana Torres Mesa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonello Cabras MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dario Baratti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marcello Deraco MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcello Deraco MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kusamura, S., Torres Mesa, P.A., Cabras, A. et al. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol 23, 1468–1473 (2016). https://doi.org/10.1245/s10434-015-4962-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-015-4962-9

Keywords

Search

Navigation